Tumor cells and influent immune cells both possess high-affinity GLUT1 transporters, thus the high uptake of the lesion after immunotherapy could be a result of a mixture of immune cells and tumor cells and is non-specific. This evidence concerns the gene SLC2A1 and neoplasm.